id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
2591388,d3045b15-a87a-4806-8280-1625a202d080,Q1,"FRANCIS EDWARD & CRONIN, INC.",311314,CURE ALZHEIMER'S FUND,2021,first_quarter,MED,Issues and legislation related to Alzheimer's disease research,"HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE",20000,,0,0,2021-04-01T09:22:17.623000-04:00
2591395,35c2e6cb-2aa7-46c7-a1e5-de709afee504,Q1,"FRANCIS EDWARD & CRONIN, INC.",311314,"PATH DECISION SUPPORT SOFTWARE, LLC",2021,first_quarter,MED,Issues and legislation related to diabetes treatment and diagnosis,"HOUSE OF REPRESENTATIVES,Indian Health Service,Natl Institutes of Health (NIH),SENATE",,,0,0,2021-04-01T09:30:19.807000-04:00
2591471,98ca624f-7d5e-43a0-a3c1-b8009745a4f3,Q1,"RICHARD J. SCHOLZ, P.A. (FKA JACOBS SCHOLZ & WYLER, LLC)",400361684,PPLA,2021,first_quarter,MED,Pharmaceutical Labeling,Food & Drug Administration (FDA),18700,,0,0,2021-04-01T14:16:44.343000-04:00
2591533,2edf49dd-126a-4ed5-a40d-cacff7c3b7c1,1T,"MILLER STRATEGIES, LLC",401104313,"VIVEBIO SCIENTIFIC, LLC",2021,first_quarter,MED,Issues related to federal government approval of medical devices.,,,,0,1,2021-04-01T17:58:15.023000-04:00
2591642,08961df2-0f27-4647-be9d-2e2d53eb6235,Q1,THE HARRIS FIRM,68376,HOLISTIC INDUSTRIES INC.,2021,first_quarter,MED,Issues pertaining to cannabis CSA scheduling.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2021-04-02T13:50:09.800000-04:00
2591715,200704e2-cefd-4271-87d3-f895631b71ed,Q1,MARSHALL BRACHMAN,6848,BAYLOR SCOTT AND WHITE HEALTH -- FORMERLY BAYLOR HEALTH CARE SYSTEM,2021,first_quarter,MED,support funding for medical research programs,"HOUSE OF REPRESENTATIVES,SENATE",33000,,0,0,2021-04-02T16:54:34.247000-04:00
2591783,33a9289e-e473-4987-852e-ab1ec5c50884,Q1,"THE FEDERAL GROUP, INC.",51104,ASSOCIATION OF CLINICAL RESEARCH PROFESSIONALS,2021,first_quarter,MED,Issues relating to clinical research,"Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",20000,,0,0,2021-04-02T23:34:01.107000-04:00
2591817,dbdf5989-3dc2-45e2-979d-ed2de8d59d77,Q1,NATURAL RESOURCE RESULTS LLC,321555,SHINE MEDICAL TECHNOLOGIES,2021,first_quarter,MED,Support funding at NNSA for Moly-99 domestic production facility construction.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2021-04-03T13:12:22.663000-04:00
2591920,02c0da91-6b0e-41dc-b87a-f32d40a7503a,Q1,LIVE OAK STRATEGIES,401105683,X. LABS,2021,first_quarter,MED,Issues related to public safety and healthcare technologies,"HOUSE OF REPRESENTATIVES,SENATE,White House Office",30000,,0,0,2021-04-05T10:45:34.653000-04:00
2592047,58df3616-ad0a-487b-88ac-976ac09aad9c,Q1,RAY C CULVER III,11468,ARKANSAS CHILDREN'S HOSPITAL,2021,first_quarter,MED,FY2022 Agricultural Appropriations bill funding for USDA ARS human nutrition research centers,"HOUSE OF REPRESENTATIVES,SENATE",5000,,0,0,2021-04-05T15:21:50.513000-04:00
2592773,35669c8c-7d33-4339-a0e4-f49646cee9a3,Q1,MARSHFIELD CLINIC HEALTH SYSTEM,57830,MARSHFIELD CLINIC HEALTH SYSTEM,2021,first_quarter,MED,"COVID-19, agricultural occupational health, NIOSH","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,60000,0,0,2021-04-08T13:25:52.390000-04:00
2593150,9b9d1dc2-56e6-479d-9738-94d3c15d34cb,Q1,DNV USA INC.,400488400,"DNV USA, INC.",2021,first_quarter,MED,"Infection prevention, mitigation, and response for cruise ships.","Centers For Disease Control & Prevention (CDC),HOUSE OF REPRESENTATIVES,SENATE,State, Dept of (DOS),U.S. Coast Guard (USCG)",,40000,0,0,2021-04-10T22:58:00.487000-04:00
2593294,606d2710-68fd-4efb-be01-89ffeadee063,Q1,DQB INTERNATIONAL,291834,TEXAS BIOMEDICAL RESEARCH INSTITUTE,2021,first_quarter,MED,"FY 2022 Labor, HHS Appropriations Bill","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2021-04-12T11:23:04.897000-04:00
2593359,317042e3-1abb-4588-bf15-d35923cb55b0,Q1,MCDERMOTT+ LLC,401103287,COALITION FOR 21ST CENTURY MEDICINE,2021,first_quarter,MED,Issues concerning regulation of laboratory-developed tests.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",40000,,0,0,2021-04-12T12:15:50.700000-04:00
2593413,9303938f-42dd-4808-b1a6-aed35334e4fe,Q1,BEN BARNES GROUP LP,5415,ENVIGO RMS LLC,2021,first_quarter,MED,Medical/Disease Research,"HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2021-04-12T13:30:41.130000-04:00
2593522,2ac02d79-16ab-4bba-9159-e3a34bde1ee4,Q1,THE PRENDA GROUP LLC,401104543,UV-CONCEPTS,2021,first_quarter,MED,"Emergency response to COVID-19 Pandemic. Assistance to Hospitals / First Responders / Medical facilities etc. for patients, visitors, and healthcare workers. ULTRAVIOLET LIGHT ENCLOSURE TECHNOLOGY FOR BROAD APPLICATIONS IN HEALTHCARE AND NON-HEALTHCARE SECTORS. Monitoring COVID-19 Stimulus Packages and appropriations. Coronavirus Response and Relief H.R. 1319","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2021-04-12T15:31:00-04:00
2593703,2084ac44-cd72-4c53-a100-54cca90fee90,Q1,"MOLNLYCKE HEALTH CARE US, LLC",401104898,"MOLNLYCKE HEALTH CARE US, LLC",2021,first_quarter,MED,Personal Protective Equipment and Medical Research,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,60000,0,0,2021-04-12T18:23:43.250000-04:00
2593783,13198801-55b5-4c72-8602-87e5cf3b905e,Q1,THE NATIONAL ALLIANCE FOR EYE AND VISION RESEARCH,314055,THE NATIONAL ALLIANCE FOR EYE AND VISION RESEARCH,2021,first_quarter,MED,Support for the National Institutes of Health; Support for the National Eye Institute; Support for medical research activities at the Department of Defense,"HOUSE OF REPRESENTATIVES,SENATE",,66489,0,0,2021-04-13T08:40:01.637000-04:00
2594306,9198b70e-6485-43bc-abba-010a1c5df4e0,Q1,O'NEILL AND ASSOCIATES,73134,"POINT32HEALTH SERVICES, INC. (FORMERLY TUFTS HEALTH PLAN)",2021,first_quarter,MED,"healthcare, medical","HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2021-04-13T14:38:21.353000-04:00
2594324,c16f0ddd-71d2-4580-9bf1-099957cabce8,Q1,O'NEILL AND ASSOCIATES,73134,ANALOGIC,2021,first_quarter,MED,medical technology,"HOUSE OF REPRESENTATIVES,SENATE",14750,,0,0,2021-04-13T14:51:41.370000-04:00
2594552,a3b6f88b-774c-4f52-b9d2-7af3486fa27a,Q1,TODD STRATEGY GROUP,401103321,ORGANIZE.ORG,2021,first_quarter,MED,Organ procurement policy.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",30000,,0,0,2021-04-13T17:04:16.387000-04:00
2594577,5142dc4f-b3e2-4cfd-a2bb-1ae7317bbaf0,Q1,INFECTIOUS DISEASES SOCIETY OF AMERICA,54836,INFECTIOUS DISEASES SOCIETY OF AMERICA,2021,first_quarter,MED,"Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants.","Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,75000,0,0,2021-04-13T17:21:32.727000-04:00
2594690,f5d363d4-3f2b-443e-819d-04160b0f082f,Q1,"THE CJR GROUP, INC.",288293,UNIVERSITY HOSPITALS HEALTH SYSTEM,2021,first_quarter,MED,Issues related to COVID-19 and funding for hospitals,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2021-04-13T20:24:08.317000-04:00
2594939,a2f88783-e055-496e-9a34-0abf9156f686,Q1,"FEDERAL SOLUTIONS, LLC",311371,MISSISSIPPI STATE UNIVERSITY,2021,first_quarter,MED,Labor/HHS/Education Appropriations: Provisions relating to disease research,"Education, Dept of,HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Oceanic & Atmospheric Administration (NOAA),SENATE",50000,,0,0,2021-04-14T11:31:24.177000-04:00
2595226,f2e5d50c-0fe5-48dc-95e7-fab756f8794d,Q1,"UNIVERSITY OF MARYLAND, BALTIMORE (UMB)",401103161,"UNIVERSITY OF MARYLAND, BALTIMORE (UMB)",2021,first_quarter,MED,NONE,"HOUSE OF REPRESENTATIVES,SENATE",,10000,0,0,2021-04-14T13:44:24.407000-04:00
2595474,12c1484d-73af-4e14-a9f5-718e4ec7773d,Q1,STANFORD UNIVERSITY,36492,STANFORD UNIVERSITY,2021,first_quarter,MED,"H.R. 1319 
American Rescue Plan Act of 2021

H.R.708; S168
Temporary Reciprocity to Ensure Access to Treatment Act

Health Professions programs","Energy, Dept of,Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE,State, Dept of (DOS)",,90000,0,0,2021-04-14T16:06:00.697000-04:00
2595583,bc593f4e-8372-4d89-8c31-fa624b9cf72e,1T,"WARD AND SMITH, P.A.",44674,MED-EL CORPORATION,2021,first_quarter,MED,Fair bidding process for Defense contracts regarding cochlear implants and medical technology.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",10000,,0,1,2021-04-14T16:55:32.220000-04:00
2595779,58fedfd2-cdc3-47be-b7cf-2e2b95b60a1f,Q1,"REPUBLIC CONSULTING, LLC",401016871,IQVIA,2021,first_quarter,MED,Monitored health Data Policy.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2021-04-15T08:39:42.810000-04:00
2595995,3a6ea7c3-d254-46b6-9a14-0bc3698a8105,Q1,AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS,52105,AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS,2021,first_quarter,MED,"Supporting the Peer-Reviewed Orthopaedic Research Program (PRORP). PRORP is a
competitive grant program that funds research pertaining to extremity war injuries.","HOUSE OF REPRESENTATIVES,SENATE",,248040,0,0,2021-04-15T11:09:43.300000-04:00
2596007,b21125cb-579d-42a7-a4a2-055a5d3ad315,Q1,"THE CONAFAY GROUP, LLC",401004840,"HAWAII BIOTECH, INC.",2021,first_quarter,MED,seek support for medical countermeasures.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2021-04-15T11:19:47.157000-04:00
2596034,08f0d849-e83a-4d74-9b1f-004f4e579ed4,Q1,"THE CONAFAY GROUP, LLC",401004840,ACADIA PHARMACEUTICALS INC.,2021,first_quarter,MED,Pharmaceutical Research,,10000,,0,0,2021-04-15T11:33:52.357000-04:00
2596056,6b91f2d1-f77a-4962-b592-c36f164cbd10,Q1,"THE CONAFAY GROUP, LLC",401004840,"ROIVANT SCIENCES, INC.",2021,first_quarter,MED,Support for medical/disease research.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2021-04-15T11:45:59.840000-04:00
2596084,5bb2f0ca-07e0-4a80-8c69-cb8b505f1487,Q1,"THE CONAFAY GROUP, LLC",401004840,"EMERJA, INC. (FORMERLY KNOWN AS WHEEL BIOLOGY, INC.)",2021,first_quarter,MED,Seek support for research and development funding.,,,,0,0,2021-04-15T12:06:09.323000-04:00
2596107,bc76eed4-cfc0-45c3-bda4-0361923bf32c,Q1,"THE CONAFAY GROUP, LLC",401004840,LYSOVANT SCIENCES INC.,2021,first_quarter,MED,support medical disease research.,,,,0,0,2021-04-15T12:14:14.247000-04:00
2596152,d87a81f7-5c87-4725-8c41-a3a2a1ba6878,Q1,"THE CONAFAY GROUP, LLC",401004840,CENTIVAX,2021,first_quarter,MED,support for medical/disease research.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2021-04-15T12:24:22.920000-04:00
2596179,c9fccb6b-f962-4c59-863c-6e70ff831cf1,Q1,"THE CONAFAY GROUP, LLC",401004840,"ATEA PHARMACEUTICALS, INC.",2021,first_quarter,MED,Support for medical/disease research.,,30000,,0,0,2021-04-15T12:35:30.390000-04:00
2596188,da2ec1d0-22fc-48cd-8234-850c77718653,Q1,"THE CONAFAY GROUP, LLC",401004840,"CURIA GLOBAL, INC. (FORMERLY KNOWN AS ALBANY MOLECULAR RESEARCH, INC.)",2021,first_quarter,MED,Federal support to advance medical research,"Health & Human Services, Dept of (HHS)",10000,,0,0,2021-04-15T12:38:32.707000-04:00
2596235,a3a78771-c692-47de-aa62-5ab9053e6529,Q1,"THE CONAFAY GROUP, LLC",401004840,"LUNGPACER MEDICAL USA, INC",2021,first_quarter,MED,seek support for research and development funding.,"Defense, Dept of (DOD),Health & Human Services, Dept of (HHS)",,,0,0,2021-04-15T13:19:56.707000-04:00
2596251,f3e38128-0e6e-4ff8-82f4-81ec0642a8dc,Q1,RYAN COSTELLO STRATEGIES,401105569,CARDIOL THERAPEUTICS,2021,first_quarter,MED,"No specific lobbying issues this quarter, determining applicable research grant opportunities","HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",40000,,0,0,2021-04-15T13:36:01.103000-04:00
2596339,7faec0a4-7ff2-4c47-bfc5-e71ea29c93c2,Q1,MICHAEL N. MCCARTY LAW OFFICE PLLC,401104300,AMERICAN MEDICAL TECHNOLOGISTS,2021,first_quarter,MED,"Support S. 236, the Tracking COVID-19 Variants Act; support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; monitor legislative efforts to regulated laboratory-developed tests (LDTs); support initiatives to improve COVID-19 testing supply chains.","HOUSE OF REPRESENTATIVES,SENATE,White House Office",10000,,0,0,2021-04-15T14:17:26.553000-04:00
2596390,6471f83a-97bc-4294-b1b9-1a5a742d00ca,Q1,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2021,first_quarter,MED,Focus interactions with the Agency for Healthcare Research and Quality (AHRQ) on the issue of Quality of Medication Therapy Management Services delivered programs authorized by the Patient Protection and Affordable Care Act (PPACA PL 111-148) and Medicare Part D plans.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,144981,0,0,2021-04-15T14:34:43.143000-04:00
2596426,c7483284-0e71-45c4-9029-5c7406c1cd2b,Q1,STRATEGIC MARKETING INNOVATIONS,60550,"IGM BIOSCIENCES, INC.",2021,first_quarter,MED,Antibody therapy for COVID-19,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2021-04-15T14:58:54.787000-04:00
2596430,379ad285-4834-4c5d-b6c3-0a1b5ccdbbf1,Q1,STRATEGIC MARKETING INNOVATIONS,60550,INTRIVO DIAGNOSTICS,2021,first_quarter,MED,Antigen Testing Technology,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2021-04-15T15:01:56.417000-04:00
2596578,0d69ea1e-417d-4eac-811c-52b6716fbeb1,Q1,IPOLICY SOLUTIONS,401105127,ASSOCIATION FOR MOLECULAR PATHOLOGY,2021,first_quarter,MED,"No bill number, Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
No bill number, Verified Innovative Testing in American Laboratories (VITAL) Act","Centers For Disease Control & Prevention (CDC),HOUSE OF REPRESENTATIVES,SENATE",42000,,0,0,2021-04-15T16:12:45.657000-04:00
2596587,2ac61c8c-cbbf-4663-a04d-17691e1621f9,Q1,IPOLICY SOLUTIONS,401105127,INVITAE INC.,2021,first_quarter,MED,"Emergency Use Authorization for COVID-19 Diagnostics
S.236 - Tracking COVID-19 Variants Act
CDC Advanced Molecular Detection Program","Centers For Disease Control & Prevention (CDC),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",75000,,0,0,2021-04-15T16:23:47.607000-04:00
2596609,550197d3-6fd4-4e31-a2b5-0f025aefafdb,Q1,IPOLICY SOLUTIONS,401105127,EVERLY HEALTH (FORMERLY KNOWN AS EVERLYWELL),2021,first_quarter,MED,Emergency Use Authorization for at home test collection,"HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2021-04-15T16:32:52.317000-04:00
2596672,48c32028-ee05-482f-8820-3818f45f78e1,Q1,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,312496,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,2021,first_quarter,MED,"CHGME, NIH, PACT ACT,","Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office",,30890,0,0,2021-04-15T17:01:11.273000-04:00
2596809,6c20741b-dc92-4e86-a1a0-afd806c39cf8,Q1,FAEGRE DRINKER BIDDLE & REATH LLP,12631,AMERICAN SOCIETY OF TROPICAL MEDICINE AND HYGIENE,2021,first_quarter,MED,Public Health Programs for Infectious and Tropical Disease; Tracking COVID 19 Variants Act; National Defense Authorization Act provisions related to malaria research.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2021-04-15T19:35:59.060000-04:00
2596885,acb94e50-cb27-417c-ab5e-50de6f2cb4ec,Q1,MICHIGAN TECHNOLOGICAL UNIVERSITY,25181,MICHIGAN TECHNOLOGICAL UNIVERSITY,2021,first_quarter,MED,Discussed issues of interest related to higher education for the COVID-19 pandemic.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2021-04-16T07:39:22.833000-04:00
2596946,35af9a1a-1510-4135-9220-445df6ec85df,Q1,AMERICAN PHYSICAL THERAPY ASSOCIATION,3093,AMERICAN PHYSICAL THERAPY ASSOCIATION,2021,first_quarter,MED,"NIH Rehab issues
APTA role with NIH
Traumatic brain injury research
Support of work done at CDC Injury Center on elder adult falls, TBI, youth sports concussions
NIH Research and Development funding
PT role in childhood obesity
Relocate TBI State Grant Program to ACL
NIDILRR - Rehab research
Nomination to NIH Committees
Safety of Children in School (Restraint & Seclusion)
Falls and Falls Prevention
Outpatient Therapy Modernization and Stabilization Act","Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,Small Business Administration (SBA),Social Security Administration (SSA),Veterans Affairs, Dept of (VA),White House Office",,240544,0,0,2021-04-16T09:05:40.763000-04:00
2597618,50dda657-e4b2-4946-b517-6ff1bc83e7c9,Q1,AMERICAN PHARMACISTS ASSOCIATION,3071,AMERICAN PHARMACISTS ASSOCIATION,2021,first_quarter,MED,H.R.747 -- Access to Technology and Equipment for Same-day Tests Act,,,35000,0,0,2021-04-16T12:33:19.073000-04:00
2597980,803df0bd-3390-4c71-a415-885f1ba15f16,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,WOMEN FIRST RESEARCH COALITION,2021,first_quarter,MED,Increasing women's health research,"HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",10000,,0,0,2021-04-16T14:08:53.837000-04:00
2598038,da6f55e3-0e1a-4271-8f20-66486da7285b,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,DEFENSE HEALTH RESEARCH CONSORTIUM,2021,first_quarter,MED,"FY22 Defense Appropriations Act, Defense Health Research Programs","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2021-04-16T14:26:16.947000-04:00
2598048,0eb23fbb-6c8f-4aed-a68c-000038a2af87,Q1,"EFB ADVOCACY, LLC",401104430,UNITED FOR MEDICAL RESEARCH,2021,first_quarter,MED,Funding Issues Related to the National Institutes of Health,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2021-04-16T14:30:20.947000-04:00
2598086,ee974e53-72c9-463f-9308-4ac0b52593f6,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,PANCREATIC CANCER ACTION NETWORK (PANCAN),2021,first_quarter,MED,"cancer research at DoD and NIH
FY 22 Defense Appropriations Act, Peer-Reviewed Pancreatic Cancer Research Program
FY 22 Labor-HHS-Education Act, NIH research on pancreatic cancer","HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2021-04-16T14:41:29.310000-04:00
2598112,955f6d03-f6f9-46b5-998d-16736bc3dc0b,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,FOUNDATION FOR PERIPHERAL NEUROPATHY,2021,first_quarter,MED,"FY22 Defense Appropriations Act, DoD funding for peripheral neuropathy research","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2021-04-16T14:44:32.563000-04:00
2598197,0fe03caf-fb8a-4c41-9f52-fb6d90992217,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,TUBEROUS SCLEROSIS ALLIANCE,2021,first_quarter,MED,"FY22 Defense Appropriations Act, Tuberous Sclerosis Complex Research Program
FY22 Labor-HHS-Appropriations Act, NIH and CDC research on tuberous sclerosis complex
NIH research on tuberous sclerosis complex","HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2021-04-16T15:05:01.157000-04:00
2598241,6fd90043-a77d-4147-a492-cd218c0902e8,Q1,BUCHANAN INGERSOLL & ROONEY PC,55291,"AMIVAS, LLC",2021,first_quarter,MED,FDA post-approval of malaria products,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2021-04-16T15:19:14.007000-04:00
2598250,efa813f3-32f4-4112-891b-031134d02075,Q1,"MCHUGH LEMAY ASSOC., LLC",401105253,CLARK STREET ASSOCIATES LLC ON BEHALF OF QORVO,2021,first_quarter,MED,Issues related to COVID testing - no specific legislation.,"Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2021-04-16T15:22:17.023000-04:00
2598255,997f391a-8150-42b1-8724-8b516d26f496,Q1,"COMPASS MANAGEMENT PARTNERS, INC.",401105171,THE LIVING LEGACY FOUNDATION OF MARYLAND,2021,first_quarter,MED,Regulations impacting accountability requirements at organ procurement organizations; organ donation matters,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2021-04-16T15:23:18.310000-04:00
2598281,33901d14-3e95-465d-a483-10b6d44c3d57,Q1,BUCHANAN INGERSOLL & ROONEY PC,55291,GENERIC ANIMAL DRUG ALLIANCE,2021,first_quarter,MED,Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry.,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2021-04-16T15:31:24.800000-04:00
2598332,5f78a63d-a9f7-4277-a1b6-0b82b7d989f5,Q1,CLARK STREET ASSOCIATES,401105692,QORVO,2021,first_quarter,MED,Issues related to COVID testing - no specific legislation.,"Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office",190000,,0,0,2021-04-16T15:43:41.130000-04:00
2598398,c7d3cd31-8b01-4070-9642-a7fdb5ece4bf,Q1,SIDLEY AUSTIN LLP,35230,CORD BLOOD ASSOCIATION,2021,first_quarter,MED,Legislative and Federal agency activities related to the Stem Cell Therapeutic and Research Reauthorization Act of 2015.,"Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),White House Office",20000,,0,0,2021-04-16T15:56:59.177000-04:00
2598451,eec188ab-5846-4fae-bab3-c912b8bf1965,Q1,NATIONAL ASSOCIATION OF SPINE SPECIALISTS,400395865,NATIONAL ASSOCIATION OF SPINE SPECIALISTS,2021,first_quarter,MED,Supporting the Peer-Reviewed Orthopaedic Research Program (PRORP). PRORP is acompetitive grant program that funds research pertaining to extremity war injuries.,"HOUSE OF REPRESENTATIVES,SENATE",,63506,0,0,2021-04-16T16:09:14.757000-04:00
2598575,bafa1a2d-6a27-46e5-a064-9dc7f60e739d,Q1,BLUEBIRD STRATEGIES,401105447,MYOTONIC,2021,first_quarter,MED,Increasing funding for Myotonic Dystrophy research. Fiscal year 2020 defense appropriations legislation. Peer Review Medical Research Program and Congressional Directed Medical Research Program.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,,0,0,2021-04-16T16:44:44.413000-04:00
2598620,d5de6104-fbf3-4fa6-911c-23c59dacbed7,Q1,BLUEBIRD STRATEGIES,401105447,"MYRIAD GENETICS, INC.",2021,first_quarter,MED,Legislation to regulate clinical labs under CLIA and FDA.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2021-04-16T17:02:54.243000-04:00
2598953,ce8bdefa-672e-47e6-be55-391281be6858,Q1,HAWLEY LLC,401105460,MLA ASSOCIATES ON BEHALF OF CLARK STREET ASSOCIATES LLC ON BEHALF OF QORVO,2021,first_quarter,MED,Issues related to pathogen for COVID 19 and other diseases testing.,"Centers For Disease Control & Prevention (CDC),Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE",30000,,0,0,2021-04-17T09:13:14.527000-04:00
2598994,861753d3-7ae5-48e8-96a8-3227790c429c,Q1,FORBES-TATE,400976792,"AMGEN USA, INC.",2021,first_quarter,MED,Issues related to Biosimilars.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2021-04-17T10:05:03.157000-04:00
2599015,25f1bd84-095b-49e4-8725-cd484aa89f12,Q1,FORBES-TATE,400976792,CALIFORNIA LIFE SCIENCES ASSOCIATION,2021,first_quarter,MED,Issues related to the life sciences industry; Issues related to drug pricing and international reference pricing.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2021-04-17T10:29:10.167000-04:00
2599223,3de3dc87-c154-4d42-9564-7c81113d280f,Q1,"DESIMONE CONSULTING, LLC",400931695,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA),2021,first_quarter,MED,"Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2021-04-17T13:18:59.457000-04:00
2599493,cf222d3f-5d4e-4488-9169-69e26eb43612,Q1,CAPITOL COUNSEL LLC,313715,"BLUE EARTH DIAGNOSTICS, INC.",2021,first_quarter,MED,To gain support for adequate Medicare reimbursement for diagnostic radiopharmaceuticals; Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2021-04-17T16:24:20.077000-04:00
2599500,2cd7ef58-319c-451b-8926-f14c507f2530,Q1,CAPITOL COUNSEL LLC,313715,"EMD SERONO, INC.",2021,first_quarter,MED,Monitoring and engaging on health policy proposals coming before the House of Representatives and the Administration pertaining to the availability and pricing of prescription drugs.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2021-04-17T16:34:23.210000-04:00
2599508,0173986e-7b78-49f2-be67-362542e3660e,Q1,CAPITOL COUNSEL LLC,313715,MASSACHUSETTS BIOTECHNOLOGY COUNCIL,2021,first_quarter,MED,Monitor health and tax legislation pertaining to the biotechnology industry.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2021-04-17T16:38:24.670000-04:00
2599644,6f8e6655-4c07-4ae0-b642-7c37a4276b5e,Q1,AMERICAN SOCIETY OF ADDICTION MEDICINE,401104864,AMERICAN SOCIETY OF ADDICTION MEDICINE,2021,first_quarter,MED,"Submitted comments on the Interim Final Rule on the Implementation of the SUPPORT Act regarding dispensing and administering controlled substances for medication-assisted treatment

Provided technical assistance on language in the Lessening Addiction by Enhancing Labeling Opioids Act so that any new label would not inappropriately refer to buprenorphine 

Discussions with Congressional offices regarding prescriber education, substance use disorder curricula grants, and opioid analgesics prescription limiation provisions in conjunction with the Comprehensive Addiction Recovery Act

Supported and provided technical assistance regarding the re-introduction of the Medication Access and Trainng Expansion Act of 2021 (HR 2067) and supported its simultaneous passage with the Mainstreaming Addiction Treatment Act of 2021 (HR 1384)

Suggested grant eligibility and Medicaid and Medicare related changes regarding provider reimbursement bump and substance use disorder coverage in conjunction with the possible reintroduction of the CARE Act of 2021.

Supported passage of the Medicaid Reentry Act (HR 955/S 285) and its inclusion in the American Rescue Plan

Discussion with ONDCP staff regarding drug policy priorities in 2021

Advocated for creation of a new safe harbor provision to the Federal Anti-Kickback Statute to protect the use of cash and cash-equivalent payments offered as part of contingency management in the treatment of substance use disorders

Supported the Tele-Mental Health Improvement Act, which would require group health plans and insurers to cover mental health and addiction telehealth services during the COVID-19 public health emergency

Advocated for increased FY 22 appropriations for HRSA's Mental Health and Substance Use Disorders Training Demonstration program, SAMHSA's expansion of practitioner education grant program, and HRSA's Substance Use Disorder (SUD) Workforce Loan Repayment Program, among other SUD workforce-related appropriation increases in conjunction with other coalitions

Supprted the Quit Because of COVID-19 Act and increased appropriations for the CDC regarding tobacco prevention and cessation activities

Supported the Resident Physician Shortage Reduction Act, which would increase the number of Medicare GME slots by 14,000 over 7 years

Advocated for changes to a draft opioid treatment program bill to make permanent certain COVID-19 flexibilities allowed to states for unsupervised doses, as well as ""time in treatment"" regulatory changes and to permit pharmacy dispensing of methadone for opioid use disorder treatment for certain experienced cohorts of physician prescribers

Advocated for new provisions in the American Rescue Treatment Act regarding increasing Medicaid reimbursment for addiction treatment providers","Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,90000,0,0,2021-04-18T07:09:07.443000-04:00
2599952,0732acab-2111-470d-9553-5c6a5c264daa,Q1,TIBER CREEK GROUP,20744,JAZZ PHARMACEUTICALS,2021,first_quarter,MED,"Issues related to the FDA and S. 3032 - the FDA STATES Act, and Health and Human Services pertaining to CBD policies.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2021-04-18T16:51:37.873000-04:00
2599974,59833718-da19-40da-b856-c2db94b023b0,Q1,"MARCHIBRODA GROUP, LLC",401105875,ALLIANCE FOR CELL THERAPY NOW,2021,first_quarter,MED,"Advocacy for increased federal funding of clinical trials for cell-based therapies for COVID-19 and other serious, life-threatening conditions in both the American Rescue Act Plan of 2021 and FY 2022 appropriations legislation","HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2021-04-18T17:28:47.103000-04:00
2599976,35c5ec0e-1b57-4561-93f6-a823c87631e3,Q1,OGR,48827,ATLAS SUPPLY LLC,2021,first_quarter,MED,Issues related to COVID-19 diagnostics technology.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2021-04-18T17:30:47.593000-04:00
2599979,32c04f62-4502-49f1-a430-cdf7b9a51713,Q1,OGR,48827,WEAVR HEALTH,2021,first_quarter,MED,COVID-19 serology issues,,20000,,0,0,2021-04-18T17:38:49.033000-04:00
2600054,7675276e-5d56-45bd-bb12-268110761dd7,Q1,OGR,48827,SMITHS GROUP PLC,2021,first_quarter,MED,"Medical device technology related to the opioid epidemic and the COVID-19 pandemic.
S.586, NOPAIN Act.","Bureau of Reclamation,Energy, Dept of,HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2021-04-18T18:43:05.943000-04:00
2600272,98fd49c1-92e4-4241-856d-927bece677c8,Q1,VAN SCOYOC ASSOCIATES,39837,AMERICAN ACADEMY OF ADDICTION PSYCHIATRY,2021,first_quarter,MED,"Education and training for health practitioners who deliver medication s and treatment for individuals with Substance Abuse Disorders (SUDs)

H.R.1384/S.445, Mainstreaming Addiction Treatment Act

H.R. 2067, Medication Access and Training Expansion Act","Health & Human Services, Dept of (HHS),Office of Natl Drug Control Policy (NDCP),Substance Abuse & Mental Health Services Administration (SAMHSA)",20000,,0,0,2021-04-19T06:58:07.460000-04:00
2600327,05b4c65e-bc60-448f-80c2-3aebdb8d9686,Q1,VAN SCOYOC ASSOCIATES,39837,GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION,2021,first_quarter,MED,"CDC, Infectious Diseases

E-Cigarettes related issues

NIMHD Research Endowment Revitalization Act, Entirety

Public Law 117-2, American Rescue Plan of 2021, Higher Education research related issues; and SARS CoV2 issues

Public Law 116-260, Consolidated Appropriations Act, FY2021, Higher Education research related issues; and SARS CoV2 issues","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2021-04-19T07:30:17.563000-04:00
2600334,49b92cf3-5043-4c72-a15f-7b627687f65c,Q1,VAN SCOYOC ASSOCIATES,39837,UNIVERSITY OF TOLEDO,2021,first_quarter,MED,"Higher Education research related issues; and SARS-CoV2 issues, as follows:

Implementation of Public Law 116-260, Consolidated Appropriations Act, 2021

Public Law 117-2, American Rescue Plan Act of 2021",HOUSE OF REPRESENTATIVES,20000,,0,0,2021-04-19T07:32:18.473000-04:00
2600432,6f5399e8-37a6-4736-bc96-096129936c88,Q1,VAN SCOYOC ASSOCIATES,39837,"HUMANIGEN, INC.",2021,first_quarter,MED,"Therapeutics manufacturing related issues, as follows:

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2022

Implementation of Public Law 116-260, Consolidated Appropriations Act, FY2022","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2021-04-19T07:54:35.963000-04:00
2600509,6d1a890a-90b9-465f-97f6-e7282be83030,Q1,MANATOS & MANATOS,23634,BARBARA ANN KARMANOS CANCER INSTITUTE,2021,first_quarter,MED,PPS-exemption,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2021-04-19T08:43:53.487000-04:00
2600515,fd43a031-73d7-4369-99e0-769984edfd22,Q1,HACKENSACK MERIDIAN HEALTH,401104109,HACKENSACK MERIDIAN HEALTH,2021,first_quarter,MED,"National Institutes of Health funding
Biosafety laboratories
Support for the Center for Discovery and Innovation","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE",,160000,0,0,2021-04-19T08:45:56.287000-04:00
2600699,86d682af-717a-440f-82bc-17e18ef7b004,Q1,NEOGENOMICS LABORATORIES,401105014,NEOGENOMICS LABORATORIES,2021,first_quarter,MED,"Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2021-04-19T09:31:32.477000-04:00
2600767,eb932dc7-9546-4b37-aee6-e8e607f38856,Q1,"OAK RIDGE ASSOCIATED UNIVERSITIES, INC.",401104196,"OAK RIDGE ASSOCIATED UNIVERSITIES, INC.",2021,first_quarter,MED,FY21 Omnibus Appropriations Act,"Defense, Dept of (DOD),Energy, Dept of,Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2021-04-19T09:43:46.313000-04:00
2600932,eed2ea86-2ea5-42db-b545-9b7efc79737e,Q1,MAGNET STRATEGY GROUP,401104125,MEDICAGO INC.,2021,first_quarter,MED,MED,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2021-04-19T10:09:19.747000-04:00
2601153,6a5bed25-7edc-4377-b284-bc2514dda0d9,Q1,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2021,first_quarter,MED,"Support for robust funding for federal agencies that fund medical and disease research
Support for increased federal funding for research and response efforts in response to COVID-19","Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,Natl Oceanic & Atmospheric Administration (NOAA),SENATE",,80000,0,0,2021-04-19T10:34:06.737000-04:00
2601250,8295e10b-b416-4303-957d-29a4385cce7b,Q1,"WILLIAMS AND JENSEN, PLLC",41454,GLOBAL DOWN SYNDROME FOUNDATION,2021,first_quarter,MED,Support for down syndrome research funding.,"Centers For Disease Control & Prevention (CDC),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2021-04-19T10:42:26.590000-04:00
2601700,147752c0-32f7-498e-89a0-b792c393de87,Q1,"THE CORMAC GROUP, LLC",66773,KESSLER FOUNDATION,2021,first_quarter,MED,"Appropriations, DOD, TBI Research, Veterans Issues","Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2021-04-19T11:18:18.323000-04:00
2601964,4277ae08-a5ac-4cfc-8258-55d67b3bf3f4,Q1,WAKE FOREST UNIVERSITY HEALTH SCIENCES,6781,WAKE FOREST UNIVERSITY HEALTH SCIENCES,2021,first_quarter,MED,"340 (b) program guidelines; HRSA community project funding; ""Research Investment to spark the Economy"" (RISE) Act; ""US Citizenship Act of 2021"";","Centers For Disease Control & Prevention (CDC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,150000,0,0,2021-04-19T11:36:36.693000-04:00
2601970,60c55de3-950f-4a68-a778-941237ac8b5b,Q1,"WILLIAMS AND JENSEN, PLLC",41454,ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED),2021,first_quarter,MED,"Issues related to FDA regulation of medical devices, including the Critical Medical Infrastructure Right to Repair Act.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",40000,,0,0,2021-04-19T11:37:39.060000-04:00
2601992,fc46b70f-d542-420e-bcb3-f8e15706f72e,Q1,UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL,89235,UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL,2021,first_quarter,MED,Issues related to pandemic preparedness.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Small Business Administration (SBA)",,35000,0,0,2021-04-19T11:37:42.720000-04:00
2602025,c7e86ca3-68cb-48ca-9474-11509ea23aff,Q1,"WILLIAMS AND JENSEN, PLLC",41454,BIOBOT ANALYTICS,2021,first_quarter,MED,"General education to advance policies that support wastewater based epidemiology and wastewater surveillance data analytic technology.  Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.","Centers For Disease Control & Prevention (CDC),Environmental Protection Agency (EPA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",50000,,0,0,2021-04-19T11:39:51.870000-04:00
2602040,7eaeb53d-b1b7-4d6c-9fd3-e6661b04902d,Q1,VAN SCOYOC ASSOCIATES,39837,MEDICAL UNIVERSITY HOSPITAL AUTHORITY,2021,first_quarter,MED,"Monitor Medical research and development related issues:

National Institutes of Health and various institutes and bureaus thereof

Health Resources Services Administration","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2021-04-19T11:41:56.480000-04:00
2602067,1be9dc0a-bb5c-4af4-8781-873b9e4f090f,Q1,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,"ANTHEM, INC.",2021,first_quarter,MED,"Issues related to the individual marketplace
Health insurance tax and general tax issues
Part D
H.R.1319 - American Rescue Plan Act of 2021",,50000,,0,0,2021-04-19T11:43:01.387000-04:00
2602122,d6959a96-b937-466a-a44f-7fbad0d236ba,Q1,VAN SCOYOC ASSOCIATES,39837,"ARUP LABORATORIES, INC.",2021,first_quarter,MED,"Verifying Accurate Leading-edge IVCT Development (VALID) Act, Diagnostic Lab Testing




COVID-19 Laboratory Testing related issues, as follows:

Public Law 116-260, Consolidated Appropriations Act, 2021

Public Law 117-2, American Rescue Plan Act of 2021

American Jobs Plan




Monitor Highly skilled visa related issues",SENATE,30000,,0,0,2021-04-19T11:48:14.947000-04:00
2602146,a9dc1bf2-74ec-4503-a10b-0a9b30921a60,Q1,"WILLIAMS AND JENSEN, PLLC",41454,"SANOFI, U.S.",2021,first_quarter,MED,General education about FDA approval policies and NIH research activities.,"HOUSE OF REPRESENTATIVES,SENATE,White House Office",50000,,0,0,2021-04-19T11:51:20.893000-04:00
2602185,db81d619-f89a-476f-b2de-0b7232b00df5,Q1,"WILLIAMS AND JENSEN, PLLC",41454,VERTEX PHARMACEUTICALS INCORPORATED,2021,first_quarter,MED,General education about FDA approval policies and NIH research activities.,"HOUSE OF REPRESENTATIVES,SENATE,White House Office",30000,,0,0,2021-04-19T11:53:28.387000-04:00